Table 3.
Association of side effects and post-vaccination health issues with vaccines.
| Health issues | AZD1222® (n = 228) | BBV152® (n = 30) | Total | P-Value | ||
|---|---|---|---|---|---|---|
| Myalgia | 43 (18.85%) | 9 (30%) | 52 (20.15%) | 0.153 | ||
| Fatigue | 34 (17.52%) | 2(6.67%) | 36 (13.95% | 0.220 | ||
| Sadness/Irritability | 5 (2.2%) | 1 (3.33%) | 6 (2.31%) | 0.697 | ||
| Lack of concentration/Excessive worry | 5 (2.2%) | 3 (30%) | 8 (3.1) % | 0.020⁎ | ||
| Paraesthesia | 3 (1.32%) | 0 | 3 (1.16%) | 0.527 | ||
| Ageusia | 2 (0.87%) | 0 | 2 (0.77%) | 0.481 | ||
| Cough and colds | Recently suffering | 70 (30.70%) | 9 (30%) | 79 (30.6%) | 0.938 | |
| Increase in frequency | 33 (14.47%) | 1(3.33%) | 34 (13.18%) | 0.090 | ||
| Longer recovery time | 24 (10.53%) | 2 (6.67%) | 26 (10.08%) | 0.509 | ||
| mMRC | Grade 0 | 161(70.6%) | 21(70%) | 182 (70.54%) | 0.97 | |
| Grade 1 | 53 (23.24%) | 6(20%) | 59 (22.86%) | |||
| Grade 2 | 5 (2.19%) | 1 (3.33%) | 6 (2.32%) | |||
| Grade 3 | 8 (3.51%) | 2 (6.67%) | 10 (3.88%) | |||
| Grade 4 | 1 (0.44%) | 0 | 1 (0.39%) | |||
| EQ5D5L | Mobility | No problems | 220(96.49%) | 28 (93.33%) | 248 (96.1%) | 0.562 |
| Slight problems | 4 (1.75%) | 2 (6.67%) | 6 (2.32%) | |||
| Moderate problems | 1 (0.44%) | 0 | 1 (0.4%) | |||
| Severe problems | 1 (0.44%) | 0 | 1 (0.4%) | |||
| Extreme problems | 2(0.87%) | 0 | 2(0.77%) | |||
| Selfcare | No problems | 219 (96.05%) | 28(93.33%) | 247 (95.73%) | 0.545 | |
| Slight problems | 4 (1.75%) | 1(3.33%) | 5 (1.94%) | |||
| Moderate problems | 1 (0.44%) | 1(3.33%) | 2(0.77%) | |||
| Severe problems | 1 (0.44%) | 0 | 1(0.4%) | |||
| Extreme problems | 3(1.32%) | 0 | 3(1.16%) | |||
| Usual activities | No problems | 212 (92.98%) | 28 (93.33%) | 240 (93.02%) | 0.635 | |
| Slight problems | 8 (3.51%) | 2 (6.67) | 10 (3.88%) | |||
| Moderate problems | 4 (1.75%) | 0 | 4 (1.55%) | |||
| Severe problems | 2 (0.87%) | 0 | 2 (0.77%) | |||
| Extreme problems | 2 (0.87%) | 0 | 2 (0.77%) | |||
| Pain/ Discomfort | No problems | 192 (84.21%) | 25 (83.33%0 | 217 (84.1%) | 0.473 | |
| Slight problems | 28 (12.28%) | 4(13.33%) | 32(12.4%) | |||
| Moderate problems | 1(0.44%) | 1(3.33%) | 2 (0.77%) | |||
| Severe problems | 6 (2.63%) | 0 | 6 (2.32%) | |||
| Extreme problems | 1(0.4%) | 0 | 1 (0.4%) | |||
| Anxiety/Depression | No problems | 192(84.21%) | 26 (86.67%) | 218 (84.5%) | 0.386 | |
| Slight problems | 21 (9.2%) | 4 (13.33%) | 25 (9.68%) | |||
| Moderate problems | 9(3.95%) | 0 | 9 (3.5%) | |||
| Severe problems | 4 (1.75%) | 0 | 4(1.55%) | |||
| Extreme problems | 2(0.87%) | 0 | 2(0.77%) | |||
| Duration from last jab of vaccination | 30–90 days | 46 (17.82%) | 0.941 | |||
| 91–180 days | 30 (11.6%) | |||||
| More than 180 days | 17 (6.58%) | |||||
| Side effect of vaccine | Injection site pain | 126 (55.26%) | 9(30%) | 135 (52.33%) | 0.009⁎⁎ | |
| Chills | 34 (17.52%) | 0 | 34 (13.2%) | 0.023* | ||
| Headache | 48 (21.1%) | 8(26.67%) | 56 (21.7%) | 0.483 | ||
| Myalgia | 86 (37.7%) | 10(33.33%) | 96 (37.2%) | 0.640 | ||
| Fever | 4 (1.75%) | 0 | 4 (1.55%) | 0.318 | ||
| Weakness | 2 (0.87%) | 0 | 2 (0.77%) | 0.481 | ||
| Fainting sensation | 3 (1.32%) | 0 | 3 (1.16%) | 0.388 | ||
| Nausea | 6 (2.63%) | 0 | 6 (2.32%) | 0.369 | ||
| Total | 171 (75%) | 20 (66.67%) | 191 (74.03%) | 0.328 | ||
| Leave taken from daily work | 76 (33.33%) | 3(10%) | 79 (30.62%) | 0.009⁎⁎ | ||
Significant levels 0.05 are shown in bold.